ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1210

Optimal Definitions of Worsening Cartilage Using Sequential MRI OsteoArthritis Knee Scores (MOAKS)
Abstract Number: 1211

An Evaluation of the Efficacy, Pharmacokinetics and Safety, of the Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist RTX-GRT7039 – a Placebo-controlled Study in Patients with Osteoarthritis Knee Pain
Abstract Number: 1212

Childhood Maltreatment Increases Risk of Chronic Widespread Pain: Counterfactual Analysis of UK Biobank
Abstract Number: 1213

High Prevalence of and Medication Use in Musculoskeletal and Chronic Multisite Pain in Community-Dwelling Older Adults: The Framingham Heart Study
Abstract Number: 1214

All-Cause Mortality in Patients with Chronic Musculoskeletal Pain Using Pregabalin or Duloxetine: A Retrospective Cohort Study in US Veterans
Abstract Number: 1215

Mortality in US Veterans with Musculoskeletal Conditions Using Cyclobenzaprine or Baclofen
Abstract Number: 1216

Subcutaneous Methylnaltrexone Treatment of Opioid-Induced Constipation in Adults with Rheumatic Conditions
Abstract Number: 1217

Medical and Non-Medical Cannabis Use by Rheumatology Patients: A Study of over 2000 Patients in California
Abstract Number: 1218

Randomized, Double-Blind, Placebo-Controlled Confirmatory Phase 3 Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Fibromyalgia
Abstract Number: 1219

Association Between Fibromyalgia and Serum Levels of Calcitonin Gene-Related Peptide and Vascular Endothelial Growth Factor: A Meta-Analysis
Abstract Number: 1220

Fibromyalgia’s Under-Representation in Rheumatology Literature: A Ten-Year Analysis of Disease-Specific Article Distribution
Abstract Number: 1221

Efficacy of Immersive Virtual Reality-based Biofeedback on Chronic Pain and Daily Life Impact in Fibromyalgia: A Pilot Randomized Controlled Trial
Abstract Number: 1222

Large Language Model-driven Sentiment Analysis for Facilitating Fibromyalgia Diagnosis
Abstract Number: 1223

Community Based Study of Prevalence and Social Factors for Chronic Pain and Fibromyalgia in Women from Western India
Abstract Number: 1224

Occupational Stress and Fibromyalgia Among Healthcare Professionals in Abu Dhabi Region, United Arab Emirates: A Cross-sectional Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].